Could biologic drugs offer a better way to treat lupus kidney disease?

NCT ID NCT07340463

Recruiting now Disease control Sponsor: Nanjing University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether biologic drugs (belimumab or telitacicept) can improve kidney outcomes in people with active lupus nephritis better than standard therapy. About 50 participants will be randomly assigned to one of three treatment groups for six months. The goal is to see if these targeted drugs can help more patients achieve complete kidney remission with fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Belimumab or Telitacicept (biologic drugs) plus glucocorticoids, with or without mycophenolate mofetil
What this could lead to: If successful, this could point toward a more targeted, potentially safer treatment option for lupus nephritis that reduces reliance on standard immunosuppressants.
What could go wrong: This is a small, early-phase exploratory trial with only 50 participants, so results may not apply broadly. Biologics can cause serious infections or allergic reactions, and the study does not yet prove long-term safety or effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS (LN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lupus nephritis systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUPUS NEPHRITIS (LN) SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Contacts and locations

Locations

Clinical Research Ethics Committee of the General Hospital of Eastern Theater Command of the People's Liberation Army
RECRUITING

Nanjing, Jiangsu, 210016, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.